WHO prequalifies Serum Institute of India’s quadrivalent HPV vaccine, CERVAVAC | Explained
The development is significant for India as well as the global effort to prevent cervical cancer
The World Health Organization (WHO) has granted prequalification to India's Serum Institute of India's quadrivalent human papillomavirus (HPV) vaccine, CERVAVAC. This marks the first time an Indian-made quadrivalent HPV vaccine has received WHO prequalification. The prequalification, effective from September 25, 2026, signifies that CERVAVAC meets WHO standards for quality, safety, and efficacy after rigorous evaluation.
CERVAVAC is India's first gender-neutral quadrivalent HPV vaccine, targeting HPV types 6, 11, 16, and 18, and is licensed for use in individuals aged 9 to 26 years in India. This achievement is significant for both India and global efforts to prevent cervical cancer, as cervical cancer caused an estimated 604,000 new cases and 342,000 deaths in 2020.
India launched its national HPV vaccination program in February 2026, initially targeting 14-year-old girls with a free dose, and has administered over 80 lakh doses by September 2025. The vaccine's prequalification enhances India's access to international procurement channels, potentially benefiting HPV vaccination programs in low- and middle-income countries.
While WHO prequalification does not automatically replace existing vaccines in national programs, it strengthens India's position as a domestic manufacturer and could promote competition and supply security for future HPV vaccine procurement.
Rewritten by urgent.news; may contain errors — check the original.
Source: thehindu.com